Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SUVEN.NSthis companySuven Life Sciences Limited	₹279.95	-10.86×	5.07×	421.72×	-9.9×	-95.9%	-589.3%	-4077.7%	-3884.1%	-46.7%	-47.6%	-10.1%	0.03×	1.19×	-1,838.51×	17.69×	0.0%	1	106.05	1	D+
CIPLA.NSCipla Limited	₹1,403.80	25.49×	2.87×	3.51×	15.19×	112.4%	42.7%	16.7%	13.8%	11.3%	9.8%	2.6%	0.02×	-0.06×	86.67×	3.44×	1.3%	4	9.92	4	A-
DRREDDY.NSDr. Reddy's Laboratories Limited	₹1,385.00	24.38×	2.77×	3.11×	14.13×	25.1%	52.8%	13.8%	12.8%	11.4%	7.5%	2.9%	0.24×	0.94×	12.42×	1.8×	0.6%	7	5.66	3	B+
EMCURE.NSEmcure Pharmaceuticals Ltd.	₹2,216.20	32.72×	6.11×	3.29×	17.14×	-27.7%	38.9%	14.9%	10.0%	18.7%	15.0%	1.6%	0.31×	0.75×	9.56×	1.43×	0.2%	—	—	1	C-
GLENMARK.NSGlenmark Pharmaceuticals Limited	₹2,671.10	44.17×	5.72×	3.54×	21.53×	-44.3%	47.6%	23.5%	8.0%	13.0%	20.1%	3.2%	0.06×	-0.21×	19.16×	1.77×	0.2%	7	6.63	1	D+
LUPIN.NSLupin Limited	₹2,025.00	19.82×	4.71×	3.78×	12.45×	95.9%	52.9%	24.7%	19.1%	23.8%	17.8%	4.9%	0.29×	0.11×	15.87×	1.9×	0.5%	4	—	3	B
Peer median	—	25.49×	4.71×	3.51×	15.19×	25.1%	47.6%	16.7%	12.8%	13.0%	15.0%	2.9%	0.24×	0.11×	15.87×	1.8×	0.5%	6	6.63	3	—